eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2020
vol. 16
 
Share:
Share:
more
 
 
abstract:
Original paper

Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients

Beytullah Cakal
1
,
Sinem Cakal
1
,
Oguz Karaca
1
,
Mehmet Onur Omaygenc
1
,
Filiz Kizilirmak Yilmaz
1
,
Haci Murat Gunes
1
,
Ozgur Ulas Ozcan
1
,
Arzu Yıldırım
1
,
Bilal Boztosun
1

1.
Department of Cardiology, Istanbul Medipol University, Istanbul, Turkey
Adv Interv Cardiol 2020; 16, 4 (62): 391–398
Online publish date: 2021/01/04
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The largest amount of evidence for bioresorbable vascular scaffold (BVS) use in clinical practice derives from Absorb trials and registries. Comparison of Absorb BVS with metallic stents resulted in increased rates of target lesion failure and device thrombosis in the Absorb BVS group. We investigated whether all BVS platforms created equal outcomes. At 3-year follow-up novolimus-eluting BVS (Desolve Elixir Medical Corp., Sunnyvale, CA) achieved better outcomes compared with Absorb BVS. The scaffold thrombosis rate is still high with Absorb BVS despite pre- and post- dilatation. No scaffold thrombosis was present with Desolve BVS.
keywords:

coronary artery disease, percutaneous coronary intervention, bioresorbable scaffolds

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe